RecruitingNot a traditional drug phaseobservationalRules rewrite

Not a traditional drug phase: Emotional Reactivity Experimental Protocol for Alcohol Use Disorder

The goal of this watch-and-measure (no experimental treatment required) study is to investigate emotional recognition and emotional reactivity in individuals with severe Alcohol Use Disorder (sAUD), Major Depressive Disorder (major depression), comorbid sAUD and depressive symptoms (sAUD+DS), and healthy controls. The main questions this study aims to answer are: * Do individuals with sAUD, major depression, sAUD+DS, and healthy controls exhibit different patterns of emotional recognition and emotional reactivity in response to dynamic emotional stimuli?

Official registry: https://clinicaltrials.gov/study/NCT07925281 · Université Catholique de Louvain · enrollment listed as 280

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 280 people at Brussels. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Emotional Reactivity in Severe Alcohol Use Disorder and Major Depressive Disorder: a Multidimensional Approach Combining Dynamic Emotional Stimuli, Eye Tracking, Pupillometry, Electrodermal and Cardiac Activity, and Biological Measures of Stress and Interoception

Interventions: Emotional Reactivity Experimental Protocol

Primary outcome (registry wording): Multidimensional assessment of emotional recognition and emotional reactivity to dynamic emotional stimuli

Who it is for (from inclusion criteria)

Ages 18 Years to 70 Years
All participants must:
Have normal or corrected-to-normal vision, without ocular conditions that could interfere with eye-tracking or pupillometry data quality
Patients with severe Alcohol Use Disorder (sAUD)
Meet DSM-5 criteria for severe Alcohol Use Disorder
Be tested during the third week of abstinence
Have no history of neurological, endocrinal, or infectious disease, diagnosed anxiety or depressive disorder, or other substance use disorder (except tobacco)
Patients with Major Depressive Disorder (major depression)

Who the registry excludes

Cognitive impairment, uncorrected visual deficits, or any condition preventing understanding of instructions or reliable task performance (e.g., major attention or comprehension difficulties);
Ophthalmological conditions that could compromise eye-tracking or pupillometry data quality;
Dermatological conditions or excessive sweating that may interfere with electrodermal and cardiac activity recording;
Cardiac conditions or devices that could affect ECG recording (e.g., pacemaker, defibrillator, severe uncontrolled arrhythmias), or use of medications strongly influencing heart rate
Acute intoxication or withdrawal state at the time of testing;
Current diagnosis of psychotic disorder, bipolar disorder, or neurological disease;
Ongoing participation in another treatment or clinical study that could interfere with behavioral or physiological measures;

Public study contact (from the registry)

Edelweiss Touron, PhD

+32470052024

edelweiss.touron@uclouvain.be

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Cliniques Universitaires Saint-Luc — Brussels, Belgium, Belgium (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07925281 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07925281?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07925281?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary